Aurobindo Pharma Limited - Asset Resilience Ratio

Latest as of March 2026: 1.28%

Aurobindo Pharma Limited (AUROPHARMA) has an Asset Resilience Ratio of 1.28% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Aurobindo Pharma Limited (AUROPHARMA) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Rs7.47 Billion

≈ $80.81 Million USD Cash + Short-term Investments

Total Assets

Rs585.02 Billion

≈ $6.33 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2004–2026)

This chart shows how Aurobindo Pharma Limited's Asset Resilience Ratio has changed over time. See AUROPHARMA net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Aurobindo Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AUROPHARMA company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs7.47 Billion	1.28%
Total Liquid Assets	Rs7.47 Billion	1.28%

Asset Resilience Insights

Limited Liquidity: Aurobindo Pharma Limited maintains only 1.28% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Aurobindo Pharma Limited Industry Peers by Asset Resilience Ratio

Compare Aurobindo Pharma Limited's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%
Guizhou Xinbang Pharmaceutical Co Ltd SHE:002390	Drug Manufacturers - Specialty & Generic	0.01%

Annual Asset Resilience Ratio for Aurobindo Pharma Limited (2004–2026)

The table below shows the annual Asset Resilience Ratio data for Aurobindo Pharma Limited.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2026-03-31	1.28%	Rs7.47 Billion ≈ $80.81 Million	Rs585.02 Billion ≈ $6.33 Billion	-9.87pp
2025-03-31	11.15%	Rs55.52 Billion ≈ $600.42 Million	Rs497.85 Billion ≈ $5.38 Billion	-0.04pp
2024-03-31	11.19%	Rs50.43 Billion ≈ $545.34 Million	Rs450.72 Billion ≈ $4.87 Billion	-0.24pp
2023-03-31	11.42%	Rs45.57 Billion ≈ $492.82 Million	Rs398.90 Billion ≈ $4.31 Billion	+8.38pp
2022-03-31	3.05%	Rs10.33 Billion ≈ $111.77 Million	Rs339.22 Billion ≈ $3.67 Billion	+2.31pp
2021-03-31	0.73%	Rs2.48 Billion ≈ $26.86 Million	Rs338.54 Billion ≈ $3.66 Billion	+0.02pp
2020-03-31	0.71%	Rs2.06 Billion ≈ $22.24 Million	Rs289.28 Billion ≈ $3.13 Billion	-0.55pp
2019-03-31	1.26%	Rs3.33 Billion ≈ $35.97 Million	Rs264.54 Billion ≈ $2.86 Billion	+0.89pp
2018-03-31	0.37%	Rs773.90 Million ≈ $8.37 Million	Rs211.01 Billion ≈ $2.28 Billion	+0.08pp
2017-03-31	0.29%	Rs470.00 Million ≈ $5.08 Million	Rs162.49 Billion ≈ $1.76 Billion	+0.23pp
2016-03-31	0.06%	Rs98.70 Million ≈ $1.07 Million	Rs159.20 Billion ≈ $1.72 Billion	-0.09pp
2015-03-31	0.15%	Rs196.50 Million ≈ $2.13 Million	Rs129.14 Billion ≈ $1.40 Billion	+0.15pp
2014-03-31	0.00%	Rs300.00K ≈ $3.24K	Rs94.90 Billion ≈ $1.03 Billion	0.00pp
2013-03-31	0.00%	Rs400.00K ≈ $4.33K	Rs72.78 Billion ≈ $787.07 Million	-0.30pp
2012-03-31	0.30%	Rs186.80 Million ≈ $2.02 Million	Rs62.38 Billion ≈ $674.58 Million	+0.30pp
2011-03-31	0.00%	Rs400.00K ≈ $4.33K	Rs58.72 Billion ≈ $635.06 Million	0.00pp
2008-03-31	0.00%	Rs600.00K ≈ $6.49K	Rs36.34 Billion ≈ $393.06 Million	+0.00pp
2007-03-31	0.00%	Rs500.00K ≈ $5.41K	Rs35.06 Billion ≈ $379.21 Million	0.00pp
2006-03-31	0.00%	Rs500.00K ≈ $5.41K	Rs26.89 Billion ≈ $290.85 Million	+0.00pp
2005-03-31	0.00%	Rs300.00K ≈ $3.24K	Rs21.30 Billion ≈ $230.33 Million	0.00pp
2004-03-31	0.00%	Rs300.00K ≈ $3.24K	Rs18.66 Billion ≈ $201.79 Million	--

pp = percentage points

About Aurobindo Pharma Limited

NSE:AUROPHARMA India Drug Manufacturers - Specialty & Generic

Market Cap

$8.69 Billion

Rs803.63 Billion INR

Market Cap Rank

#2509 Global

#97 in India

Share Price

Rs1396.70

Change (1 day)

-0.82%

52-Week Range

Rs1022.20 - Rs1517.50

All Time High

Rs1568.05